UroGen Pharma announces third quarter 2026 financial results: Can URGN break above $34.94?

UroGen Pharma announces third quarter 2026 financial results: Can URGN break above $34.94?
UroGen Pharma stock holds steady today

UroGen Pharma is scheduled to report its third quarter 2026 financial results. The stock is little changed on the day, trading near $34.4.

Highlights

  • UroGen Pharma will announce third quarter 2026 financial results and hold an earnings call at 10:00 AM ET.
  • Analyst coverage is heavily positive, with 28 of 32 rating the stock a buy and none at sell.
  • UroGen Pharma stock is little changed on the day, trading near $34.4.

UroGen Pharma announced it will report its third quarter 2026 financial results. The company also said it will host a live earnings call at 10:00 AM ET. Of the 32 analysts covering the stock, 28 rate it a buy and none rate it a sell.

Split daily structure as price holds above MA-200 after early gap

UroGen Pharma stock opened with a gap up from $34.36 to $34.78 before giving back part of that advance. The price remains confined beneath the MA-20 and MA-50 but is still holding above the MA-200, reflecting a split daily structure. RSI at 38.9 is nearing oversold territory, which suggests that recent declines are starting to reach a stretched condition. The nearest resistance is the weekly high at $34.94.

Downside risk leads as odds tilt toward lower close

A close above $34.94 would indicate buyers are ready to continue the move, while a drop below $32.4 would show the advance is being faded. In today's session the stock opened with a gap up from $34.36 to $34.78, but has since surrendered a portion of those gains. Although the past week saw a sustained move higher with a firm trend, from here downside probability stands at 58% and upside at 42% for the coming trading week. The expected trading range is $33.26 to $35.53. On the weekly chart the longer-term picture stays constructive.

Earlier, analysts noted that UroGen Pharma's technical outlook had shifted to increased downside risk as shares hovered near key support. The upcoming earnings release adds a potential catalyst to this setup, with traders now focused on whether the stock can decisively move above $34.94 resistance or risks slipping back toward the $33.26–$35.53 expected trading range in the coming week.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.